Loading…

Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis

Background Severe and therapy‐resistant pruritus is the most prominent feature of macular (MA) and lichen (LA) amyloidosis that leads to further amyloid deposition by recurrent frictional trauma to the epidermis. Of the various therapeutic modalities with variable success, the most encouraging and b...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 1998-12, Vol.37 (12), p.949-954
Main Authors: Özkaya-Bayazit, Esen, e Kavak, Ayş, Güngör, Havva, Özarmagan, Güzin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5520-3838c649974cdfbea60ced8014f14069de3ffbf3219e16b866cf36b4a1d67b533
cites cdi_FETCH-LOGICAL-c5520-3838c649974cdfbea60ced8014f14069de3ffbf3219e16b866cf36b4a1d67b533
container_end_page 954
container_issue 12
container_start_page 949
container_title International journal of dermatology
container_volume 37
creator Özkaya-Bayazit, Esen
e Kavak, Ayş
Güngör, Havva
Özarmagan, Güzin
description Background Severe and therapy‐resistant pruritus is the most prominent feature of macular (MA) and lichen (LA) amyloidosis that leads to further amyloid deposition by recurrent frictional trauma to the epidermis. Of the various therapeutic modalities with variable success, the most encouraging and beneficial effect has been observed with topical dimethyl sulfoxide (DMSO) therapy. In a previous study, we achieved marked clinical improvement in nine of 10 patients in a daily treatment regimen over 6–20 weeks, but relapses occurred in the post‐treatment follow‐up period. The aims of this study are to investigate whether the patients would benefit from intermittent therapy and to determine the optimal application interval of DMSO to maintain the relief of symptoms. Methods Thirteen patients with histopathologically verified cutaneous amyloidosis (five MA, two LA and six biphasic) were enrolled in the study. They were treated once daily with a 50 or 100% DMSO solution until pruritus disappeared. Then, DMSO was applied at increasing intervals until the widest effective application interval for maintenance of relief was reached. Patients were regularly followed‐up by a scoring system for pruritus, papules, and pigmentation, control biopsies, photographs, blood biochemistry, and side‐effects. Results The mean time required for the disappearance of pruritus was 4.1 weeks. Remarkable flattening of the papules was achieved after an average therapy period of 9 weeks. After a total therapy period of 6.5 months, a nearly 50% remission in pigmentation and >70% flattening of papules were achieved. The widest effective DMSO application interval was 8.6 days. The side‐effects of therapy were contact urticaria, desquamation, burning sensation, and garlic‐like breath odor, which were more prominent with the higher concentration of DMSO. In interval therapy, side‐effects were tolerated more easily than in daily therapy. No reduction of amyloid deposits was revealed in control biopsies. Conclusions Locally applied DMSO can break the vicious “pruritus–amyloid deposition–pruritus” cycle in patients with MA and LA. In addition to its daily use, interval therapy seems to maintain this effect and enables patients to tolerate side‐effects more easily.
doi_str_mv 10.1046/j.1365-4362.1998.00600.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69135468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37928814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5520-3838c649974cdfbea60ced8014f14069de3ffbf3219e16b866cf36b4a1d67b533</originalsourceid><addsrcrecordid>eNqNkE1rFDEYx4NY6tr6EYQg4m3GZJLJJuBFqq1bVqWo1FvI5AWzzkzGZIbufnsznaUFT57yhP9LnvwAgBiVGFH2dldiwuqCElaVWAheIsQQKvdPwGoRGKmeghVCGBcC1eIZeJ7SLl9JhekpOBWcc0KrFbjZ9KONnR9H249wShYGB8cweK1aaHxnx1-HFqapdWHvjYW-h53SU6siVL2BgxqWuTu0wZuQfDoHJ061yb44nmfgx-XH7xefiu3Xq83F-22h67pCBeGEa0aFWFNtXGMVQ9oajjB1mCImjCXONS7vKyxmDWdMO8IaqrBh66Ym5Ay8WXqHGP5MNo2y80nbtlW9DVOSTGBSU8az8dU_xl2YYp93k1VVcS4Qmtv4YtIxpBStk0P0nYoHiZGckcudnMnKGbmckct75HKfoy-P_VPTWfMQPDLO-uujrlKm6qLqtU-P_YxSdP-fd4vtzrf28N_Py831hzzkeLHEfRrt_iGu4m_J1mRdy9svV3L7GbOf39C1vCV_ATjrqy8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222889003</pqid></control><display><type>article</type><title>Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis</title><source>Wiley</source><creator>Özkaya-Bayazit, Esen ; e Kavak, Ayş ; Güngör, Havva ; Özarmagan, Güzin</creator><creatorcontrib>Özkaya-Bayazit, Esen ; e Kavak, Ayş ; Güngör, Havva ; Özarmagan, Güzin</creatorcontrib><description>Background Severe and therapy‐resistant pruritus is the most prominent feature of macular (MA) and lichen (LA) amyloidosis that leads to further amyloid deposition by recurrent frictional trauma to the epidermis. Of the various therapeutic modalities with variable success, the most encouraging and beneficial effect has been observed with topical dimethyl sulfoxide (DMSO) therapy. In a previous study, we achieved marked clinical improvement in nine of 10 patients in a daily treatment regimen over 6–20 weeks, but relapses occurred in the post‐treatment follow‐up period. The aims of this study are to investigate whether the patients would benefit from intermittent therapy and to determine the optimal application interval of DMSO to maintain the relief of symptoms. Methods Thirteen patients with histopathologically verified cutaneous amyloidosis (five MA, two LA and six biphasic) were enrolled in the study. They were treated once daily with a 50 or 100% DMSO solution until pruritus disappeared. Then, DMSO was applied at increasing intervals until the widest effective application interval for maintenance of relief was reached. Patients were regularly followed‐up by a scoring system for pruritus, papules, and pigmentation, control biopsies, photographs, blood biochemistry, and side‐effects. Results The mean time required for the disappearance of pruritus was 4.1 weeks. Remarkable flattening of the papules was achieved after an average therapy period of 9 weeks. After a total therapy period of 6.5 months, a nearly 50% remission in pigmentation and &gt;70% flattening of papules were achieved. The widest effective DMSO application interval was 8.6 days. The side‐effects of therapy were contact urticaria, desquamation, burning sensation, and garlic‐like breath odor, which were more prominent with the higher concentration of DMSO. In interval therapy, side‐effects were tolerated more easily than in daily therapy. No reduction of amyloid deposits was revealed in control biopsies. Conclusions Locally applied DMSO can break the vicious “pruritus–amyloid deposition–pruritus” cycle in patients with MA and LA. In addition to its daily use, interval therapy seems to maintain this effect and enables patients to tolerate side‐effects more easily.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1046/j.1365-4362.1998.00600.x</identifier><identifier>PMID: 9888342</identifier><identifier>CODEN: IJDEBB</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Administration, Topical ; Adult ; Amyloidosis - complications ; Amyloidosis - drug therapy ; Biological and medical sciences ; Dimethyl Sulfoxide - administration &amp; dosage ; Drug Administration Schedule ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pruritus - drug therapy ; Pruritus - etiology ; Skin Diseases - drug therapy ; Skin, nail, hair, dermoskeleton</subject><ispartof>International journal of dermatology, 1998-12, Vol.37 (12), p.949-954</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Dec 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5520-3838c649974cdfbea60ced8014f14069de3ffbf3219e16b866cf36b4a1d67b533</citedby><cites>FETCH-LOGICAL-c5520-3838c649974cdfbea60ced8014f14069de3ffbf3219e16b866cf36b4a1d67b533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1644053$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9888342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Özkaya-Bayazit, Esen</creatorcontrib><creatorcontrib>e Kavak, Ayş</creatorcontrib><creatorcontrib>Güngör, Havva</creatorcontrib><creatorcontrib>Özarmagan, Güzin</creatorcontrib><title>Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Background Severe and therapy‐resistant pruritus is the most prominent feature of macular (MA) and lichen (LA) amyloidosis that leads to further amyloid deposition by recurrent frictional trauma to the epidermis. Of the various therapeutic modalities with variable success, the most encouraging and beneficial effect has been observed with topical dimethyl sulfoxide (DMSO) therapy. In a previous study, we achieved marked clinical improvement in nine of 10 patients in a daily treatment regimen over 6–20 weeks, but relapses occurred in the post‐treatment follow‐up period. The aims of this study are to investigate whether the patients would benefit from intermittent therapy and to determine the optimal application interval of DMSO to maintain the relief of symptoms. Methods Thirteen patients with histopathologically verified cutaneous amyloidosis (five MA, two LA and six biphasic) were enrolled in the study. They were treated once daily with a 50 or 100% DMSO solution until pruritus disappeared. Then, DMSO was applied at increasing intervals until the widest effective application interval for maintenance of relief was reached. Patients were regularly followed‐up by a scoring system for pruritus, papules, and pigmentation, control biopsies, photographs, blood biochemistry, and side‐effects. Results The mean time required for the disappearance of pruritus was 4.1 weeks. Remarkable flattening of the papules was achieved after an average therapy period of 9 weeks. After a total therapy period of 6.5 months, a nearly 50% remission in pigmentation and &gt;70% flattening of papules were achieved. The widest effective DMSO application interval was 8.6 days. The side‐effects of therapy were contact urticaria, desquamation, burning sensation, and garlic‐like breath odor, which were more prominent with the higher concentration of DMSO. In interval therapy, side‐effects were tolerated more easily than in daily therapy. No reduction of amyloid deposits was revealed in control biopsies. Conclusions Locally applied DMSO can break the vicious “pruritus–amyloid deposition–pruritus” cycle in patients with MA and LA. In addition to its daily use, interval therapy seems to maintain this effect and enables patients to tolerate side‐effects more easily.</description><subject>Administration, Topical</subject><subject>Adult</subject><subject>Amyloidosis - complications</subject><subject>Amyloidosis - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Dimethyl Sulfoxide - administration &amp; dosage</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pruritus - drug therapy</subject><subject>Pruritus - etiology</subject><subject>Skin Diseases - drug therapy</subject><subject>Skin, nail, hair, dermoskeleton</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqNkE1rFDEYx4NY6tr6EYQg4m3GZJLJJuBFqq1bVqWo1FvI5AWzzkzGZIbufnsznaUFT57yhP9LnvwAgBiVGFH2dldiwuqCElaVWAheIsQQKvdPwGoRGKmeghVCGBcC1eIZeJ7SLl9JhekpOBWcc0KrFbjZ9KONnR9H249wShYGB8cweK1aaHxnx1-HFqapdWHvjYW-h53SU6siVL2BgxqWuTu0wZuQfDoHJ061yb44nmfgx-XH7xefiu3Xq83F-22h67pCBeGEa0aFWFNtXGMVQ9oajjB1mCImjCXONS7vKyxmDWdMO8IaqrBh66Ym5Ay8WXqHGP5MNo2y80nbtlW9DVOSTGBSU8az8dU_xl2YYp93k1VVcS4Qmtv4YtIxpBStk0P0nYoHiZGckcudnMnKGbmckct75HKfoy-P_VPTWfMQPDLO-uujrlKm6qLqtU-P_YxSdP-fd4vtzrf28N_Py831hzzkeLHEfRrt_iGu4m_J1mRdy9svV3L7GbOf39C1vCV_ATjrqy8</recordid><startdate>199812</startdate><enddate>199812</enddate><creator>Özkaya-Bayazit, Esen</creator><creator>e Kavak, Ayş</creator><creator>Güngör, Havva</creator><creator>Özarmagan, Güzin</creator><general>Blackwell Science Ltd</general><general>Blackwell Science</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199812</creationdate><title>Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis</title><author>Özkaya-Bayazit, Esen ; e Kavak, Ayş ; Güngör, Havva ; Özarmagan, Güzin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5520-3838c649974cdfbea60ced8014f14069de3ffbf3219e16b866cf36b4a1d67b533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Administration, Topical</topic><topic>Adult</topic><topic>Amyloidosis - complications</topic><topic>Amyloidosis - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Dimethyl Sulfoxide - administration &amp; dosage</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pruritus - drug therapy</topic><topic>Pruritus - etiology</topic><topic>Skin Diseases - drug therapy</topic><topic>Skin, nail, hair, dermoskeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Özkaya-Bayazit, Esen</creatorcontrib><creatorcontrib>e Kavak, Ayş</creatorcontrib><creatorcontrib>Güngör, Havva</creatorcontrib><creatorcontrib>Özarmagan, Güzin</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Özkaya-Bayazit, Esen</au><au>e Kavak, Ayş</au><au>Güngör, Havva</au><au>Özarmagan, Güzin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>1998-12</date><risdate>1998</risdate><volume>37</volume><issue>12</issue><spage>949</spage><epage>954</epage><pages>949-954</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><coden>IJDEBB</coden><abstract>Background Severe and therapy‐resistant pruritus is the most prominent feature of macular (MA) and lichen (LA) amyloidosis that leads to further amyloid deposition by recurrent frictional trauma to the epidermis. Of the various therapeutic modalities with variable success, the most encouraging and beneficial effect has been observed with topical dimethyl sulfoxide (DMSO) therapy. In a previous study, we achieved marked clinical improvement in nine of 10 patients in a daily treatment regimen over 6–20 weeks, but relapses occurred in the post‐treatment follow‐up period. The aims of this study are to investigate whether the patients would benefit from intermittent therapy and to determine the optimal application interval of DMSO to maintain the relief of symptoms. Methods Thirteen patients with histopathologically verified cutaneous amyloidosis (five MA, two LA and six biphasic) were enrolled in the study. They were treated once daily with a 50 or 100% DMSO solution until pruritus disappeared. Then, DMSO was applied at increasing intervals until the widest effective application interval for maintenance of relief was reached. Patients were regularly followed‐up by a scoring system for pruritus, papules, and pigmentation, control biopsies, photographs, blood biochemistry, and side‐effects. Results The mean time required for the disappearance of pruritus was 4.1 weeks. Remarkable flattening of the papules was achieved after an average therapy period of 9 weeks. After a total therapy period of 6.5 months, a nearly 50% remission in pigmentation and &gt;70% flattening of papules were achieved. The widest effective DMSO application interval was 8.6 days. The side‐effects of therapy were contact urticaria, desquamation, burning sensation, and garlic‐like breath odor, which were more prominent with the higher concentration of DMSO. In interval therapy, side‐effects were tolerated more easily than in daily therapy. No reduction of amyloid deposits was revealed in control biopsies. Conclusions Locally applied DMSO can break the vicious “pruritus–amyloid deposition–pruritus” cycle in patients with MA and LA. In addition to its daily use, interval therapy seems to maintain this effect and enables patients to tolerate side‐effects more easily.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>9888342</pmid><doi>10.1046/j.1365-4362.1998.00600.x</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0011-9059
ispartof International journal of dermatology, 1998-12, Vol.37 (12), p.949-954
issn 0011-9059
1365-4632
language eng
recordid cdi_proquest_miscellaneous_69135468
source Wiley
subjects Administration, Topical
Adult
Amyloidosis - complications
Amyloidosis - drug therapy
Biological and medical sciences
Dimethyl Sulfoxide - administration & dosage
Drug Administration Schedule
Female
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pruritus - drug therapy
Pruritus - etiology
Skin Diseases - drug therapy
Skin, nail, hair, dermoskeleton
title Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T17%3A09%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intermittent%20use%20of%20topical%20dimethyl%20sulfoxide%20in%20macular%20and%20papular%20amyloidosis&rft.jtitle=International%20journal%20of%20dermatology&rft.au=%C3%96zkaya-Bayazit,%20Esen&rft.date=1998-12&rft.volume=37&rft.issue=12&rft.spage=949&rft.epage=954&rft.pages=949-954&rft.issn=0011-9059&rft.eissn=1365-4632&rft.coden=IJDEBB&rft_id=info:doi/10.1046/j.1365-4362.1998.00600.x&rft_dat=%3Cproquest_cross%3E37928814%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5520-3838c649974cdfbea60ced8014f14069de3ffbf3219e16b866cf36b4a1d67b533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222889003&rft_id=info:pmid/9888342&rfr_iscdi=true